[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Dallas VA Medical Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":72},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100381287","phase-2-mitochondrial-capacity-boost-in-als-micabo-als-trial-100381287",false,"NCT04244630","Mitochondrial Capacity Boost in ALS (MICABO-ALS) Trial","MICABO-ALS","Inclusion Criteria:\n\n1. A clinical diagnosis by a study investigator of laboratory-supported probable, probable, or definite ALS, according to a modified El Escorial criterion (Appendix 2).\n2. 21 to 80 years of age inclusive.\n3. If patients are taking riluzole for ALS, they must be on a stable dose for at least thirty days prior to the baseline visit.\n4. Willing and able to give signed informed consent that has been approved by the Institutional Review Board (IRB).\n\nExclusion Criteria:\n\n1. Diagnosis of other neurodegenerative diseases (Parkinson disease, Alzheimer disease, etc.).\n2. Clinically significant history of unstable medical illness (unstable angina, advanced cancer, etc.) over the last 30 days.\n3. Infection with the human immunodeficiency virus (HIV)\n4. Limited mental capacity such that the patient cannot provide written informed consent or comply with evaluation procedures.\n5. History of recent alcohol or drug abuse or noncompliance with treatment or other experimental protocols. 6 Receipt of any investigational drug within the past 30 days.","ALL","21 Years","80 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The purpose of this research is to investigate the validity of a previous clinical trial named EH301, which showed beneficial effects of anti-oxidant therapies in patients with amyotrophic lateral sclerosis (ALS). If validated by this study, providing over-the-counter anti-oxidants would be a simple, low risk, low-cost approach to significantly slow or stop the progression of ALS, for which currently no effective treatment exists. It is currently thought that oxidative stress is a major cause of ALS. The study investigators are therefore planning to expand the original scope of the previous trial by including anti-oxidants at high doses that were not previously used. All of these compounds are considered safe.",[27],"Amyotrophic Lateral Sclerosis (ALS)","RECRUITING","2025-08-19",{"date":31,"type":32},"2025-08-24","ACTUAL",{"date":34,"type":32},"2023-11-02",{"date":36,"type":21},"2025-12",{"name":38,"class":39},"Dallas VA Medical Center","FED",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":52,"conditions":53,"keywords":57,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":40},"100363950","phase-2-evaluating-the-effect-of-itraconazole-on-pathologic-complete-response-rates-in-esophageal-cancer-100363950","NCT04018872","Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer","A Phase II Trial Evaluating the Effectiveness of Itraconazole in Improving Pathologic Complete Response Rates in Patients With Esophageal Cancer Through Inhibition of the Hedgehog and AKT Signaling Pathways","Inclusion Criteria:\n\n* Patients diagnosed with localized (locoregional) esophageal cancer\n* Patients diagnosed with localized (locoregional) gastroesophageal junction cancer\n\nExclusion Criteria:\n\n* Patients unwilling or unable to provide informed consent\n* Patients with QTc\\>450ms\n* Patients with a history of symptomatic congestive heart failure\n* Patients with LFT's\\>3xULN\n* Patients who are pregnant\n* Patients with a known allergy to itraconazole","18 Years",{"count":50,"type":21},78,[24],"Esophageal cancer, which has a low 5-year overall survival rate for all stages (\\\u003C20%) , is increasing in incidence. Previous studies have shown that the Hedgehog (Hh) and AKT signaling pathways are activated in a significant proportion of esophageal cancers. Itraconazole, a widely used anti-fungal medication, has been shown to inhibit various pathways involved in esophageal cancer tumorigenesis including Hh and AKT. In this phase II clinical trial, the investigators aim to evaluate the effect of itraconazole as a neoadjuvant therapy following standard of care chemoradiation in the treatment of locoregional esophageal and gastroesophageal junction carcinomas.",[54,55,56],"Esophagus Adenocarcinoma","Esophagus Squamous Cell Carcinoma","Gastroesophageal Junction Adenocarcinoma",[58,59,60,61,62,63],"itraconazole","esophageal neoplasms","esophagus","esophagogastric junction","adenocarcinoma","squamous cell carcinoma","2021-11-02",{"date":66,"type":32},"2021-11-04",{"date":68,"type":32},"2019-06-24",{"date":70,"type":21},"2026-09-29",{"name":38,"class":39},""]